Core Viewpoint - American Water Works reported strong third-quarter earnings, beating estimates and showing significant revenue growth, while also announcing a merger with Essential Utilities, Inc. that is expected to enhance its market position. Financial Performance - The company reported Q3 2025 earnings per share (EPS) of $1.94, exceeding the Zacks Consensus Estimate of $1.90 by 2.1% and improving 7.8% from $1.80 in the same quarter last year [2] - Total revenues for the quarter were $1.45 billion, surpassing the Zacks Consensus Estimate of $1.32 billion by 19.6% and increasing 9.8% year-over-year [3] - Operating income reached $614 million, up 13.1% from $543 million in the previous year [5] Segment Performance - Net revenues from regulated businesses were $1.34 billion, reflecting a year-over-year increase of 10.2% [4] - Other segment revenues amounted to $108 million, up 3.8% year-over-year [4] Operating Expenses - Total operating expenses for Q3 were $837 million, a 7.3% increase from $780 million in the prior year, driven by higher employee-related and technology costs [5] Merger Announcement - The company announced a merger agreement with Essential Utilities, Inc., projected to create a leading regulated U.S. water and wastewater utility with a pro forma enterprise value of approximately $63 billion [8] - Essential shareholders will receive 0.305 shares of American Water for each share they own, representing a 10% premium [9] Long-Term Guidance - American Water reiterated its 2025 EPS guidance in the range of $5.70 to $5.75, with a 2026 EPS expectation of $6.02 to $6.12 [10] - The company plans to invest $3.7 billion in 2026 and anticipates long-term capital expenditures of $19-$20 billion from 2026-2030 and $46-$48 billion from 2026-2035 [11] Market Sentiment - Estimates for the stock have trended downward recently, with a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [12][14]

Core Viewpoint - DaVita HealthCare's recent earnings report indicates a mixed performance, with revenues increasing year-over-year but adjusted earnings per share falling short of estimates, leading to questions about future trends and stock performance [2][11]. Financial Performance - Adjusted earnings per share for Q3 2025 were $2.51, down 3.1% year-over-year, missing the Zacks Consensus Estimate by 23.7% [2]. - GAAP EPS for the quarter was $2.04, reflecting an 18.4% decline year-over-year [2]. - Revenues reached $3.42 billion, a 4.8% increase year-over-year, surpassing the Zacks Consensus Estimate by 0.5% [3]. - Revenue per treatment was $410.6, up 4.1% year-over-year and 1.5% sequentially [3]. Revenue Breakdown - Dialysis patient service revenues amounted to $3.29 billion, a 5.1% increase year-over-year, while other revenues were $122.1 million, down 2.3% from the previous year [4]. Treatment and Patient Metrics - Total U.S. dialysis treatments for Q3 were 7,242,725, averaging 91,680 per day, which is a 0.4% decrease sequentially [5]. - As of September 30, 2025, DaVita served approximately 293,200 patients across 3,247 outpatient dialysis centers [5]. Operational Changes - During Q3 2025, DaVita opened three dialysis centers and closed three in the U.S., while acquiring 58 and closing nine centers internationally [6]. Profitability and Margins - Gross profit decreased by 2.2% year-over-year to $1.09 billion, with a gross margin contraction of 230 basis points to 31.8% [7]. - Adjusted operating profit was $517 million, down 3.4% from the prior year, with an adjusted operating margin of 15.1%, a decrease of 130 basis points [7]. Financial Position - DaVita ended Q3 2025 with cash and cash equivalents of $736.5 million, slightly down from $739.4 million at the end of Q2 [9]. - Total debt was $10.25 billion, marginally lower than $10.26 billion at the end of Q2 [9]. - Cumulative net cash from operating activities was $1.35 billion, down from $1.47 billion a year ago [9]. Share Repurchase - In Q3 2025, DaVita repurchased 3.3 million shares for $465 million [10]. Guidance and Estimates - The adjusted earnings per share outlook for 2025 has been revised to a range of $10.35-$11.15, down from the previous guidance of $10.20-$11.30 [11]. - Consensus estimates have trended upward, with a 19.15% shift due to recent changes [12]. Industry Context - DaVita operates within the Zacks Medical - Outpatient and Home Healthcare industry, where competitors like Quest Diagnostics have shown positive performance, with a 7.9% gain over the past month [15].

Core Viewpoint - Group 1 Automotive's recent earnings report showed mixed results, with adjusted earnings per share missing estimates but revenues increasing year over year, raising questions about future performance [3][4][5]. Financial Performance - Q3 2025 adjusted EPS was $10.45, missing the Zacks Consensus Estimate of $10.64 but up 5.6% year over year [3]. - Net sales reached $5.8 billion, exceeding the Zacks Consensus Estimate of $5.63 billion and up from $5.2 billion in the previous year [3]. - New vehicle retail sales increased 9.3% to $2.81 billion, surpassing projections, while total retail new vehicles sold rose 6.5% year over year to 57,269 units [4]. - Used-vehicle retail sales rose 11.8% to $1.85 billion, exceeding forecasts, but total retail used vehicles sold increased only 6.6% to 59,574 units [5]. Segment Performance - U.S. business segment revenues rose 6.5% year over year to $4.28 billion, with gross profit increasing 5.4% to $715 million [7]. - U.K. business segment revenues jumped 20.4% to $1.50 billion, although it missed estimates, while gross profit surged 17.3% to $204.7 million [8]. Financial Position - Selling, general and administrative expenses increased 10.7% year over year to $654.9 million [9]. - Cash and cash equivalents decreased to $30.8 million from $34.4 million, while total debt rose to $3.47 billion from $2.91 billion [9]. Shareholder Actions - During the quarter, Group 1 repurchased 185,788 shares at an average price of $443.18, totaling $82.5 million, with $226.3 million remaining in the stock buyback program [10]. Market Sentiment - Since the earnings release, there has been a downward trend in estimates revision, with the consensus estimate shifting down by 7.8% [11][12]. - Group 1 Automotive holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [14].

Core Viewpoint - Ares Capital's recent earnings report shows mixed results, with core earnings meeting estimates but reflecting a decline from the previous year, driven by increased investment income and higher expenses [2][4]. Financial Performance - Core earnings for Q3 2025 were 50 cents per share, matching the Zacks Consensus Estimate but down 13.8% year-over-year [2]. - GAAP net income was $404 million or 57 cents per share, compared to $394 million or 62 cents per share in the prior-year quarter [3]. - Total investment income increased to $782 million, up approximately 1% year-over-year, surpassing the Zacks Consensus Estimate of $763.7 million [4]. Expense Analysis - Total quarterly expenses rose to $433 million, a 7.7% increase year-over-year, primarily due to higher interest and credit facility fees, as well as base management fees [4]. Portfolio Activity - The company made gross commitments of $3.92 billion to new and existing portfolio companies, remaining flat compared to the prior-year quarter [5]. - The fair value of Ares Capital's portfolio investments was $28.7 billion as of September 30, 2025, with accruing debt and other income-producing securities valued at $25.9 billion [5]. Balance Sheet Strength - As of September 30, 2025, cash and cash equivalents totaled $1.04 billion, up from $635 million as of December 31, 2024 [6]. - The company had $5.2 billion available for additional borrowings under existing credit facilities, with total outstanding debt at $15.6 billion [6]. - Total assets were $30.8 billion, and stockholders' equity was $16.5 billion, with a net asset value of $20.01 per share, up from $19.89 as of December 31, 2024 [6]. Market Sentiment - Estimates for Ares Capital have trended downward over the past month, indicating a negative sentiment among analysts [7][10]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [10]. Investment Scores - Ares Capital has a poor Growth Score of F, a Momentum Score of D, and a Value Score of D, placing it in the bottom 40% for investment strategy [9].

Core Insights - Burlington Stores reported revenue of $2.71 billion for the quarter ended October 2025, marking a year-over-year increase of 7.1% and an EPS of $1.80 compared to $1.55 a year ago [1] - The reported revenue matched the Zacks Consensus Estimate, resulting in a surprise of -0.02%, while the EPS exceeded expectations by 13.21% [1] Financial Performance Metrics - The company had 1,211 stores at the end of the period, surpassing the four-analyst average estimate of 1,199 [4] - Comparable store sales increased by 1%, which was below the average estimate of 2.4% from four analysts [4] - Net sales of $2.71 billion were above the four-analyst average estimate of $2.69 billion, reflecting a year-over-year change of +7.1% [4] - Other revenue was reported at $4.44 million, slightly below the three-analyst average estimate of $4.7 million, indicating a year-over-year decline of -1.9% [4] Stock Performance - Shares of Burlington Stores have returned +4.9% over the past month, contrasting with a -1.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Earnings Results - Workday, Inc. is set to release its third-quarter earnings results on November 25, with expected earnings of $2.17 per share, an increase from $1.89 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $2.42 billion, compared to $2.16 billion a year earlier [1] Acquisition Announcement - On November 19, Workday announced a definitive agreement to acquire Pipedream, an integration platform that connects over 3,000 business applications [2] - Following the announcement, Workday shares rose by 0.7% to close at $226.64 [2] Analyst Ratings - Citigroup analyst Steven Enders maintained a Neutral rating and increased the price target from $260 to $261 [4] - DA Davidson analyst Gil Luria also maintained a Neutral rating, raising the price target from $225 to $260 [4] - Barclays analyst Raimo Lenschow maintained an Overweight rating and increased the price target from $285 to $288 [4] - TD Cowen analyst J. Derrick Wood maintained a Buy rating but cut the price target from $310 to $290 [4] - Piper Sandler analyst Brent Bracelin upgraded the stock from Underweight to Neutral and raised the price target from $220 to $235 [4]

Core Insights - The S&P 500 closed positively on Friday, indicating a favorable market response to recent earnings reports from major companies [1] - The week saw declines in both the Nasdaq and Dow indices, with decreases of 2.7% [1] Company Performance - Nvidia's earnings report contributed to the positive sentiment in the S&P 500 [1] - Consumer giants Walmart and Target also reported earnings, influencing investor perceptions [1] Market Trends - The overall market experienced volatility, as evidenced by the declines in the Nasdaq and Dow indices during the week [1]

Core Viewpoint - Viking Therapeutics, Inc. reported a wider-than-expected loss in Q3 2025, with shares showing a slight increase of about 1% since the last earnings report, outperforming the S&P 500 [1][3]. Financial Performance - The company reported a Q3 2025 loss of 81 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 70 cents, and a significant increase from a loss of 22 cents per share in the same quarter last year [3]. - Viking Therapeutics has not generated any revenues as it currently has no approved products in its portfolio [3]. - Research and development (R&D) expenses rose to $90 million, compared to $22.8 million in the year-ago period, driven by higher costs related to clinical studies, manufacturing, and increased employee-related expenses [4]. - General and administrative expenses decreased to $8.6 million, down nearly 38% year over year, primarily due to lower legal and patent service costs and stock-related compensation expenses [5]. - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $715 million, down from $808 million as of June 30, 2025 [5]. Market Reactions - Following the earnings release, there has been a downward trend in estimates revisions, with the consensus estimate shifting down by 19.23% [6]. - The stock currently has a poor Growth Score of F, a Momentum Score of D, and a Value Score of C, placing it in the middle 20% for the value investment strategy [7]. Outlook - Estimates for Viking Therapeutics have been trending downward, indicating a negative shift in market sentiment, with a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [8].

Core Viewpoint - Lam Research reported strong Q1 fiscal 2026 earnings, surpassing expectations, with significant year-over-year growth in both revenue and earnings per share, despite a recent decline in share price [2][3][12] Financial Performance - Non-GAAP earnings per share for Q1 fiscal 2026 were $1.26, exceeding the Zacks Consensus Estimate by 4.1% and reflecting a 46.5% increase year-over-year [2] - Revenues for the first quarter reached $5.32 billion, surpassing the consensus estimate by 2% and increasing 28% from $4.17 billion in the same quarter last year [3] Revenue Breakdown - Systems revenues accounted for $3.55 billion, representing 66.6% of total revenues, up 3% from the previous quarter and 48% year-over-year [4] - Customer Support Business Group revenues were $1.77 billion, making up 33.4% of total revenues, with a 2.5% rise from the previous quarter and a slight 0.1% increase year-over-year [5] Operating Metrics - Non-GAAP gross margin improved to 50.6%, up 30 basis points from the previous quarter, while non-GAAP operating expenses rose to $831.92 million, a 1.2% increase [6] - The non-GAAP operating margin improved to 35%, reflecting a 60 basis points sequential increase [6] Balance Sheet and Cash Flow - As of September 28, 2025, Lam Research held $6.69 billion in cash and cash equivalents, an increase from $6.39 billion in the prior quarter [7] - Cash flow from operating activities decreased to $1.78 billion, down from $2.55 billion in the previous quarter, with dividends paid totaling $291.9 million and share repurchases amounting to $975.8 million [7] Guidance and Outlook - For Q2 fiscal 2026, Lam Research projects revenues of $5.2 billion (+/- $300 million), with a non-GAAP gross margin of 48.5% (+/-1%) and non-GAAP earnings per share of $1.15 (+/- $0.10) [8] - Recent estimate revisions have shown a 10.53% upward trend, indicating positive sentiment among analysts [10] - Lam Research holds a Zacks Rank 2 (Buy), suggesting expectations for above-average returns in the coming months [12]

Company Overview - Zoom Communications is valued at approximately $24 billion and generated $4.8 billion in revenue over the past year, with an operating profit of $971 million and a net income of $1.2 billion [2]. Earnings Performance - Historically, Zoom has underperformed market expectations on earnings day, often providing conservative guidance and experiencing slow enterprise growth or muted customer expansion [2]. - There have been 19 documented earnings data points over the last five years, with only 5 positive one-day (1D) returns, resulting in a positive return rate of approximately 26%. This rate increases to 40% when considering the last 3 years [9]. Trading Strategies - Traders can prepare for Zoom's earnings by either gauging historical probabilities and positioning themselves before the announcement or analyzing the relationship between immediate and medium-term returns after earnings [3]. - A less risky strategy involves assessing the correlation between short-term and medium-term returns following earnings, allowing traders to position themselves accordingly based on positive 1D returns [6]. Peer Comparison - The performance of peers can influence post-earnings stock reactions, with market expectations potentially setting in before Zoom's earnings announcements [7].